JPRN-UMIN000026739
Completed
Phase 2
The efficacy and safety of antiemetic therapy for carboplatin-containing chemotherapy-induced nausea and vomiting in patients with lung cancer. - Antiemetic therapy for carboplatin-containing chemotherapy-induced nausea and vomiting.
Second Division, Department of Internal Medicine, Hamamatsu university school of medicine0 sites30 target enrollmentStarted: April 1, 2017Last updated:
Conditionsadvanced lung cancer
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Second Division, Department of Internal Medicine, Hamamatsu university school of medicine
- Enrollment
- 30
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)patients with the history of hypersensitivity or allergy for study drugs. 2\)patients who need and use antiemetic therapy during 48h before chemotherapy. 3\)patients with severe hepatic or renal dysfunction. 4\)With convulsion. 5\)Patients who need puncture to manage ascites. 6\)Patients with complications inducing nausea and vomiting. 7\)Patients with diabetes mellitus. 8\)Patients who are judged to be inappropriate for this study.
Investigators
Similar Trials
Completed
Not Applicable
Antiemetic effectiveness and safety of aprepitant in patients with lung cancer receiving combination therapy with carboplatin.lung cancerJPRN-UMIN000010018Hamamatsu University School of Medicine134
Completed
Phase 3
The efficacy of combination antiemetic therapy with Olanzapine, Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving Moderately Emetogenic Chemotherapygastric cancer, colorectal cancerJPRN-UMIN000034383Osaka Medical Collage150
Completed
Not Applicable
Assesmentt of the efficacy of antiemetics for post procedure sedation vomiting (PPSV) in ED pediatric patientsSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0000370Ajou University270
Not yet recruiting
Not Applicable
Comparing Injection Palonosetron alone and Palonosetron with Dexamethasone for preventing vomiting in post operation period in cholecystectomy patientsHealth Condition 1: O- Medical and SurgicalCTRI/2023/11/059627Dr SHIVAKUMAR G
Active, not recruiting
Phase 1
The effectiveness of pharmacological treatment with the glucagon-like peptide-1 receptor agonist Liraglutide 3mg (Saxenda®) once-daily for weight management in forensic psychiatryEUCTR2020-003718-11-DKMental Health Center Copenhagen40